Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1 Genotype-Directed Belinostat in High-Grade Neuroendocrine Neoplasms
NCT06406465Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of belinostat in neuroendocrine carcinoma (NEC), sponsored by National Cancer Institute. Started Nov 2026; status: recruiting.
02
Drugs
belinostat
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06406465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406465.